Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.25 -0.10 (-0.19%)

Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

38 39 Next >

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death ↗

April 03, 2025

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

Via Benzinga

Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025

April 03, 2025

From Genentech

Via Business Wire

Why Is Pharma Giant Roche Stock Trading Lower On Wednesday? ↗

April 02, 2025

Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and safety for relapsing multiple sclerosis.

Via Benzinga

IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche ↗

April 02, 2025

The companies both have drugs that treat relapsing forms of multiple sclerosis.

Via Investor's Business Daily

Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis

April 02, 2025

From Genentech

Via Business Wire

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy ↗

March 19, 2025

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.

Via Benzinga

The Best Vanguard ETF to Invest $1,000 in Right Now ↗

March 18, 2025

Via The Motley Fool

Topics ETFs

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped ↗

March 12, 2025

Ignore the noise in GLP-1 stocks. Find the best value instead.

Via The Motley Fool

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion ↗

March 12, 2025

The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.

Via Investor's Business Daily

Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs ↗

March 12, 2025

Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global commercialization rights.

Via Benzinga

FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis

March 05, 2025

From Genentech

Via Business Wire

FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults

March 03, 2025

From Genentech

Via Business Wire

Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy ↗

March 03, 2025

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.

Via Benzinga

Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies

March 02, 2025

From Genentech

Via Business Wire

NovoCure Q4 EPS Misses, Revenue Matches ↗

February 27, 2025

NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.

Via The Motley Fool

Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?

February 26, 2025

Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound.

Via MarketBeat

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

February 12, 2025

From Genentech

Via Business Wire

New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis

February 07, 2025

From Genentech

Via Business Wire

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

February 04, 2025

From Genentech

Via Business Wire

Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data ↗

January 28, 2025

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD.

Via Benzinga

Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer

January 28, 2025

From Genentech

Via Business Wire

Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years ↗

January 27, 2025

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.

Via Benzinga

Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants ↗

January 21, 2025

Medical marijuana reduces benzodiazepine prescriptions, saving patients from potential risks. This threatens big pharma's profits.

Via Benzinga

Topics Cannabis

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug ↗

January 16, 2025

Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.

Via Benzinga

Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint ↗

January 13, 2025

The company is also facing off with biosimilars for standard Eylea and competition with Roche.

Via Investor's Business Daily

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact ↗

December 31, 2024

Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results.

Via Benzinga

Roche CEO Reassures No Job Cuts Despite Challenges: Report ↗

December 30, 2024

Roche Holding AG reportedly says no layoffs planned. CEO Schinecker provides pipeline updates including potential anti-obesity drug by 2029.

Via Benzinga

Topics Workforce

Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease ↗

December 19, 2024

The drug technically missed the study's primary goal. But there's still promise it could work in specific patients.

Via Investor's Business Daily

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.